Magnetic nanoparticle-samirna complex and method for preparing same
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
BioneerBioneer is a biotechnology company specializing in molecular biology, offering solutions in nucleic acid synthesis, molecular diagnostics, protein production, and laboratory automation. The company's expertise covers oligonucleotide chemistry, gene synthesis, sample preparation, molecular diagnostics, and analytical services such as mass spectrometry and sequencing, serving clinical, research, and industrial sectors globally.
Bioneer is a biotechnology company specializing in molecular biology, offering solutions in nucleic acid synthesis, molecular diagnostics, protein production, and laboratory automation. The company's expertise covers oligonucleotide chemistry, gene synthesis, sample preparation, molecular diagnostics, and analytical services such as mass spectrometry and sequencing, serving clinical, research, and industrial sectors globally.
Abstract
Provided are a SAMiRNA-magnetic nanoparticle complex capable of effectively delivering a double-stranded oligo RNA and magnetic nanoparticles into a cell and a composition capable of simultaneously performing diagnosis and therapy of diseases such as cancer, and the like, containing the same. More specifically, provided is the SAMiRNA-magnetic nanoparticle complex consisting of double-stranded oligo RNA-polymer structures in which a hydrophilic material and a second hydrophobic material are bound to the double-stranded oligo RNA by a simple covalent bond or a linker-mediated covalent bond, and the magnetic nanoparticles in which a first hydrophobic material is bound onto a surface of the magnetic material, as a core.The SAMiRNA-magnetic nanoparticle complex may have a homogeneous size by a hydrophobic interaction between the first hydrophobic material of the present invention and the second hydrophobic material of the double-stranded oligo RNA structure.In addition, the hydrophilic material and the second hydrophobic material bound to the double-stranded oligo RNA structure may improve in vivo stability of the double-stranded oligo RNA, an additionally bound ligand may deliver the SAMiRNA-magnetic nanoparticle complex into a target cell even at a relative low concentration of dosage, and the magnetic materials of the magnetic nanoparticles may be used as an imaging agent for diagnosis.
Core Innovation
The invention relates to a SAMiRNA(s)-magnetic nanoparticle(s) complex comprising magnetic nanoparticle(s) including a first hydrophobic material coated on a surface of a magnetic material. The complex further includes a structure comprising second hydrophobic material, double stranded oligo RNA, and hydrophilic material, represented by Formula (1) as A-X—R—Y—B.
In the structure, one of A and B is the hydrophilic material and the other is the second hydrophobic material, while X and Y are simple covalent bonds or linker-mediated covalent bonds, and R is the double-stranded oligo RNA. The magnetic nanoparticle is positioned in a core by hydrophobic interaction between the first hydrophobic material and the second hydrophobic material, and the structure is positioned in a shell.
The hydrophilic material of the structure is bound to the outermost side of the double-stranded oligo RNA, so that the double-stranded oligo RNA is located within the shell portion bound to the outermost hydrophilic material. Optional ligand-containing variants support target-specific interaction described as receptor-mediated endocytosis (RME), where the ligand is bound in a target-specific manner.
Claims Coverage
The document provides one independent claim defining the SAMiRNA(s)-magnetic nanoparticle(s) complex with a core-shell assembly and a specific structure representation, and multiple dependent claims that refine features by specifying classes or ranges for materials and RNA, defining linkage degradability, and adding target-specific ligand functionality for receptor-mediated endocytosis (RME).
Core-shell SAMiRNA-magnetic nanoparticle complex via hydrophobic interaction
A SAMiRNA(s)-magnetic nanoparticle(s) complex comprising magnetic nanoparticle(s) with a first hydrophobic material coated on a surface of a magnetic material and a structure comprising second hydrophobic material, double stranded oligo RNA, and hydrophilic material, wherein the magnetic nanoparticle is positioned in a core by hydrophobic interaction between the first hydrophobic material and the second hydrophobic material, the structure is positioned in a shell, and the hydrophilic material is bound to the outermost side of the double-stranded oligo RNA.
Formula-defined hydrophilic-hydrophobic-RNA structure with covalent connections
The complex where the structure is represented by Formula (1) as A-X—R—Y—B, with one of A and B being the hydrophilic material and the other being the second hydrophobic material, X and Y each being independently a simple covalent bond or a linker-mediated covalent bond, and R being the double-stranded oligo RNA.
Hydrophobic material selection for the magnetic nanoparticle coating
The complex in which the first hydrophobic material is selected from C6 to C25 aromatic compounds, C6 to C25 ethers, C6 to C25 aliphatic hydrocarbons, or C6 to C25 amines.
Double-stranded oligo RNA length constraint
The complex characterized in that the double-stranded oligo RNA has 19 to 31 nucleotides.
Magnetic nanoparticle diameter constraint
The complex defined such that the diameter is in the range of 50 to 300 nm.
Degradable or non-degradable covalent bond linkage option
The complex characterized by having a covalent bond that is either non-degradable or degradable.
Target-specific ligand enabling receptor-mediated endocytosis
A SAMiRNA-magnetic nanoparticle complex in which a ligand bound in a target-specific manner to enable receptor-mediated endocytosis (RME) is selected from target-specific antibody, aptamer, peptide, or a receptor-specific chemical material.
Overall, the claim set centers on a SAMiRNA-magnetic nanoparticle core-shell complex assembled by hydrophobic interaction, together with a Formula (1)-defined hydrophilic/hydrophobic RNA structure using simple or linker-mediated covalent bonds, further constrained by selectable hydrophobic coatings, RNA length, nanoparticle diameter, and optional degradable or non-degradable covalent linkages. Target-specific receptor-mediated endocytosis is incorporated through ligand selection.
Stated Advantages
Improved in vivo stability.
Homogeneous particle size.
Theragnosis combining siRNA/double-stranded oligo RNA therapy and magnetic imaging diagnosis.
Documented Applications
Magnetic imaging diagnosis using MRI.
Gene knockdown of survivin using SAMiRNA.
Theragnosis involving simultaneous siRNA/double-stranded oligo RNA therapy and magnetic imaging diagnosis.
Interested in licensing this patent?
